183
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG

, , , , , , , , , , , , , , & show all
Pages 250-252 | Received 10 Jun 2022, Accepted 15 Sep 2022, Published online: 13 Oct 2022
 

Disclosure statement

MO is a consultant for Daiichi Sankyo, Biosight, and Merck and is on independent data safety monitoring boards for Celgene and Glycomimetics.

Additional information

Funding

This work was supported by National Institutes of Health/National Cancer Institute (NIH/NCI; U01-CA180888 and U01-CA180819), Blood Cancer UK (Grant #13041), and Cardiff University.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.